Skip to main content
HomeDrug Comparisons
Drug bottle and Pill

Compare Ibrance vs. Verzenio

Head-to-head comparisons of medication uses, side effects, warnings, and more.

  • Ibrance (palbociclib)
    Verzenio (abemaciclib)
  • Ibrance (palbociclib)
    Verzenio (abemaciclib)

  • Summary of Ibrance vs. Verzenio

    Summary for Cyclin-dependent kinase (CDK) inhibitor
    Prescription only

    Ibrance (palbociclib) is a capsule or tablet you take by mouth to treat certain types of breast cancer, specifically hormone receptor-positive, human epidermal growth factor 2-negative (HR+, HER2‑) advanced or metastatic breast cancer. It works by blocking specific proteins called CDK4/6 to help slow down the growth of cancer cells. You usually take it once a day for 21 days, and then don’t take it for 7 days, repeating this cycle every 28 days. Ibrance (palbociclib) is also used with other medications like an aromatase inhibitor, fulvestrant, or inavolisib. Side effects include low white blood cell counts, infections, nausea, and tiredness.

    Summary for Cyclin-dependent kinase (CDK) inhibitor
    Prescription only

    Verzenio (abemaciclib) is an oral medication used to treat certain types of breast cancer. It's FDA approved for hormone receptor-positive, human epidermal growth factor 2-negative (HR+, HER2‑) breast cancer, including early and advanced or metastatic stages. This medication belongs to a group called CDK4/6 inhibitors, which slow down the growth of cancer cells. It comes as a pill that’s taken by mouth twice a day, without breaks. You might take Verzenio (abemaciclib) on its own or with hormone therapy. Common side effects include diarrhea, low white blood cell counts, and tiredness.

  • Indications of Ibrance vs. Verzenio

    Indications for
    •Advanced or metastatic breast cancer (HR+, HER2-), used with
    •An aromatase inhibitor as the first hormone-based treatment OR
    •Fulvestrant after the cancer has stopped responding to hormone-based treatment
    •Advanced or metastatic breast cancer (HR+, HER2-) with a PIK3CA mutation, used with inavolisib and fulvestrant after the cancer has come back following hormone therapy
    Indications for
    •Early breast cancer (HR+, HER2-), used with tamoxifen or an aromatase inhibitor in adults at high risk of the cancer coming back
    •Advanced or metastatic breast cancer (HR+, HER2-), used with
    •An aromatase inhibitor as the first hormone-based treatment OR
    •Fulvestrant either as the first treatment or after the cancer has stopped responding to hormone-based treatment
    •Advanced or metastatic breast cancer (HR+, HER2-), used alone if the cancer has worsened after both hormone-based treatment and chemotherapy

  • Pros and Cons of Ibrance vs. Verzenio

    Pros and Const for Cyclin-dependent kinase (CDK) inhibitor
    Pros
    •Oral pill taken at home
    •Recommended treatment option for advanced or metastatic breast cancer (HR+, HER2-)
    •Helps you live longer without the cancer getting worse compared to hormone therapy alone
    Cons
    •Raises your risk for infections, some of which can be serious
    •Requires regular blood tests to check white blood cell count
    •Not safe to take while pregnant or breastfeeding
    Pros and Const for Cyclin-dependent kinase (CDK) inhibitor
    Pros
    •Taken by mouth twice a day, every day without breaks
    •First-choice treatment option for metastatic and certain early breast cancers
    •Can be taken with or without food
    Cons
    •Can cause severe diarrhea and low white blood cells
    •Requires regular blood tests to monitor for side effects
    •Interacts with many products and medications

  • Common Side Effects of Ibrance vs. Verzenio

    Common Side Effects for

    Ibrance (palbociclib) with letrozole:

    •Low white blood cell count (up to 80%)
    •Infections (60%)
    •Tiredness (37%)
    •Nausea (35%)
    •Hair loss (33%)
    •Mouth sores (30%)
    •Diarrhea (26%)
    •Anemia (24%)

    Ibrance (palbociclib) with fulvestrant:

    •Low white blood cell count (up to 83%)
    •Infections (47%)
    •Tiredness (41%)
    •Nausea (34%)
    •Anemia (30%)
    •Mouth sores (28%)
    •Diarrhea (24%)
    •Low platelet count (23%)

    Ibrance (palbociclib) with inavolisib and fulvestrant:

    •Mouth sores (51%)
    •Diarrhea (48%)
    •Tiredness (38%)
    •Nausea (28%)
    •Rash (26%)
    •Reduced appetite (24%)
    •COVID-19 infection (23%)
    •Headache (22%)
    Common Side Effects for
    •Rise in creatinine (99%)
    •Lower white blood cell count (up to 91%)
    •Diarrhea (90%)
    •Anemia (69%)
    •Tiredness (65%)
    •Nausea (64%)
    •Reduced appetite (45%)
    •Lower platelet count (41%)
    •Stomach pain (39%)
    •Vomiting (35%)
    •Infections (31%)
    •Rise in liver enzymes (up to 31%)
    •Headache (20%)

    Note: Side effects listed above are from a study of Verzenio (abemaciclib) used alone to treat metastatic breast cancer.

  • Warnings of Ibrance vs. Verzenio

    Common Side Effects for
    •Low white blood cell counts
    •Lung problems
    •Harm to unborn baby
    Common Side Effects for
    •Diarrhea
    •Low white blood cell counts
    •Lung problems
    •Liver problems
    •Blood clots
    •Harm to unborn baby

  • Prices with our coupons for Ibrance vs. Verzenio

    Learn more about Ibrance
    Learn more about Verzenio

Compare other Breast Cancer drugs

Ibrance vs VerzenioKisqali vs Verzenio

Browse medications

View All

Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.